In the end, who ever owns the IP or rights, the only way for us to get a slice of the cake is actually to buy shares in IVX. Even if its just a RMW shell company, we should benefit from any progress. I assume the status quo will remain for RMW to take advantage of the R & D tax rebate.
IMU rising on its platform expectations, especially CF33 which IVX's INV043 has matched in results in the pre-clincal trials regarding immune system activation and memorising. If CF33 is valued 1.5b, INV043 should deserve 300m imo.
GLTA and happy buying the cheaper shares on offer.
Add to My Watchlist
What is My Watchlist?
